ShortCut(TM) Pivotal Study Update: Dedicated Transcatheter Leaflet Splitting Device
Presenter:
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Equity/Stock(s)/Options - Dura Biotech; Thubrikar Aortic Valve Inc; MicroInterventional Devices; Supira
- Consultant Fee/Honoraria/Speaker's Bureau - Meril Lifesciences; JenaValve; Admedus (Equity as well)
- Grant Support/Research Contract - Edwards Lifesciences; Abbott Vascular; Medtronic; Boston Scientific Corporation; St. Jude Medical
Video Player is loading.